What is Moxifloxacin Tablets?
Treating infections caused by certain bacteria.
Moxifloxacin Tablets tablets is a fluoroquinolone. It works by killing sensitive bacteria.
Moxifloxacin Tablets indications
Acute Bacterial Sinusitis
Moxifloxacin Tablets tablets are indicated in adult patients (18 years of age and older) for the treatment of Acute Bacterial Sinusitis caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Acute Bacterial Exacerbation of Chronic Bronchitis
Moxifloxacin Tablets tablets are indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.
Community Acquired Pneumonia
Moxifloxacin Tablets tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]),Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.
MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.
Uncomplicated Skin and Skin Structure Infections
Moxifloxacin Tablets tablets are indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.
Complicated Skin and Skin Structure Infections
Moxifloxacin Tablets tablets are indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.
Complicated Intra-Abdominal Infections
Moxifloxacin Tablets tablets are indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species.
Moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of Moxifloxacin Tablets could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Tablets tablets and other antibacterial drugs, Moxifloxacin Tablets tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Moxifloxacin Tablets?
Use Moxifloxacin Tablets tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Moxifloxacin Tablets tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Moxifloxacin Tablets tablets refilled.
- Take Moxifloxacin Tablets tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Drink plenty of liquids while taking Moxifloxacin Tablets tablets.
- Do not take a product that has magnesium, aluminum, calcium, zinc, iron, or sucralfate in it within 8 hours before or 4 hours after you take Moxifloxacin Tablets tablets. Examples of these products include antacids, multivitamins, chewable/buffered didanosine, didanosine suspension, and quinapril. Check with your doctor or pharmacist if you have a question about whether you should separate Moxifloxacin Tablets tablets from a certain food or product.
- Take Moxifloxacin Tablets tablets on a regular schedule to get the most benefit from it.
- To clear up your infection completely, take Moxifloxacin Tablets tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
- If you miss a dose of Moxifloxacin Tablets tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take more than 1 dose in the same day.
Ask your health care provider any questions you may have about how to use Moxifloxacin Tablets tablets.
Uses of Moxifloxacin Tablets in details
Moxifloxacin Tablets is used to treat bacterial infections of the respiratory tract, infections of female upper genital tract, abdominal infections and infections of skin and eye.
Moxifloxacin Tablets description
Moxifloxacin Tablets is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Moxifloxacin Tablets dosage
Dosage in Adult Patients
The dose of Moxifloxacin Tablets tablets is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.
|Type of Infection *||Dose |
Every 24 hours
|Duration † (days)|
|Acute Bacterial Sinusitis (1.1)||400 mg||10|
|Acute Bacterial Exacerbation of Chronic Bronchitis (1.2)||400 mg||5|
|Community Acquired Pneumonia (1.3)||400 mg||7–14|
|Uncomplicated Skin and Skin Structure Infections (SSSI ) (1.4)||400 mg||7|
|Complicated SSSI (1.5)||400 mg||7–21|
|Complicated Intra-Abdominal Infections (1.6)||400 mg||5–14|
|Plague (1.7) ‡||400 mg||10–14|
Oral Dosing in Adults
Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with Moxifloxacin Tablets injection may be switched to Moxifloxacin Tablets tablets when clinically indicated at the discretion of the physician.
Important Administration Instructions
Moxifloxacin Tablets Tablets
With Multivalent Cations
Administer Moxifloxacin Tablets tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution.
Moxifloxacin Tablets tablets can be taken with or without food, drink fluids liberally.
Moxifloxacin Tablets interactions
You should consult with your personal physician before you start a treatment with Moxifloxacin Tablets. This drug can interact with drugs such as herbal products, vitamins and minerals. Among these drugs there are warfarin (Coumadin); or an anti-inflammatory non-steroidal drug (NSAID) like ibuprofen (Nuprin, Motrin, and Advil), naproxen (Naprosyn, Aleve, and Anaprox), ketoprofen (Oruvail, Orudis KT, and Orudis) and other drugs that have not been mentioned here.
Please inform you personal doctor if you are following a treatment with any of the following medicines:
Heart medicines such as quinidine (Quinaglute, Cardioquin, Quinidex), procainamide (Procan SR, Pronestyl), amiodarone (Pacerone, Cordarone), sotalol (Betapace) and any other medicine of this type
Tricyclic antidepressants such as amitriptyline (Endep, Elavil), Imipramine (Tofranil), amoxapine (Asendin), thioridazine (Mellaril), mesoridazine (Serentil), and others Erythromycin (Ery-Tab, E-Mycin, E.E.S, and any other drugs of this type)
All the medicines stated above affect your regular pulse. You might need Moxifloxacin Tablets dosage adjustments or special monitoring during your treatment with Moxifloxacin Tablets if you are taking these drugs.
Moxifloxacin Tablets side effects
The following serious and otherwise important adverse reactions are discussed in greater detail in the warnings and precautions section of the label:
- Tendinopathy and Tendon Rupture
- Exacerbation of Myasthenia Gravis
- QT Prolongation
- Hypersensitivity Reactions
- Other Serious and Sometimes Fatal Reactions
- Central Nervous System Effects
- Clostridium difficile-Associated Diarrhea
- Peripheral Neuropathy that may be irreversible
- Blood Glucose Disturbances
- Development of Drug Resistant Bacteria
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Moxifloxacin Tablets in 14981 patients in 71 active controlled Phase II–IV clinical trials in different indications. The population studied had a mean age of 50 years (approximately 73% of the population was less than 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Patients received Moxifloxacin Tablets tablets 400 mg once daily oral, intravenous, or sequentially (intravenous followed by oral). Treatment duration was usually 6 to 10 days, and the mean number of days on therapy was 9 days.
Discontinuation of Moxifloxacin Tablets due to adverse reactions occurred in 5% of patients overall, 4% of patients treated with 400 mg PO, 4% with 400 mg intravenous and 8% with sequential therapy 400 mg oral/intravenous. The most common adverse reactions (>0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting. The most common adverse reaction leading to discontinuation with the 400 mg intravenous dose was rash. The most common adverse reactions leading to discontinuation with the 400 mg intravenous/oral sequential dose were diarrhea, pyrexia.
Adverse reactions occurring in 1% of Moxifloxacin Tablets hydrochloride-treated patients and less common adverse reactions, occurring in 0.1 to 1% of Moxifloxacin Tablets hydrochloride-treated patients, are shown in Tables 2 and Table 3, respectively. The most common adverse drug reactions (3%) are nausea, diarrhea, headache, and dizziness.
|System Organ Class||Adverse Reactions||% |
|Blood and Lymphatic System Disorders||Anemia||1|
|General Disorders and Administration Site Conditions||Pyrexia||1|
|Investigations||Alanine aminotransferase increased||1|
|Metabolism and Nutritional Disorder||Hypokalemia||1|
|Nervous System Disorders||Headache||4|
|System Organ Class||Adverse Reactions|
|Blood and Lymphatic System Disorders||Thrombocythemia |
|Cardiac Disorders||Atrial fibrillation |
|Ear and Labyrinth Disorders||Vertigo |
|Eye Disorders||Vision blurred|
|Gastrointestinal Disorders||Dry mouth |
Gastroesophageal reflux disease
|General Disorders and Administration Site Conditions||Fatigue |
Infusion site extravasation
|Hepatobiliary disorders||Hepatic function abnormal|
|Infections and Infestations||Candidiasis |
|Investigations||Aspartate aminotransferase increased |
Blood alkaline phosphatase increased
Electrocardiogram QT prolonged
Blood lactate dehydrogenase increased
Blood amylase increased
Blood creatinine increased
Blood urea increased
Prothrombin time prolonged
Eosinophil count increased
Activated partial thromboplastin time prolonged
Blood triglycerides increased
Blood uric acid increased
|Metabolism and Nutrition Disorders||Hyperglycemia |
|Musculoskeletal and Connective Tissue Disorders||Back pain |
Pain in extremity
|Nervous System Disorders||Dysgeusia |
|Psychiatric Disorders||Anxiety |
|Renal and Urinary Disorders||Renal failure |
|Reproductive System and Breast Disorders||Vulvovaginal pruritus|
|Respiratory, Thoracic, and Mediastinal Disorders||Dyspnea |
|Skin and Subcutaneous Tissue Disorders||Rash |
|Vascular Disorders||Hypertension |
Changes in laboratory parameters, which are not listed above and which occurred in 2% or more of patients and at an incidence greater than in controls included: increases in mean corpuscular hemoglobin (MCH), neutrophils, white blood cells (WBCs), prothrombin time (PT) ratio, ionized calcium, chloride, albumin, globulin, bilirubin; decreases in hemoglobin, red blood cells (RBCs), neutrophils, eosinophils, basophils, glucose, oxygen partial pressure (pO 2), bilirubin, and amylase. It cannot be determined if any of the above laboratory abnormalities were caused by the drug or the underlying condition being treated.
Table 4 below lists adverse reactions that have been identified during post-approval use of Moxifloxacin Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
|System Organ Class||Adverse Reaction|
|Blood and Lymphatic System Disorders||Agranulocytosis |
|Cardiac Disorders||Ventricular tachyarrhythmias (including in very rare cases cardiac arrest and torsade de pointes, and usually in patients with concurrent severe underlying proarrhythmic conditions)|
|Ear and Labyrinth Disorders||Hearing impairment, including deafness (reversible in majority of cases)|
|Eye Disorders||Vision loss (especially in the course of CNS reactions, transient in majority of cases)|
|Hepatobiliary Disorders||Hepatitis (predominantly cholestatic) |
Hepatic failure (including fatal cases)
Acute hepatic necrosis
|Immune System Disorders||Anaphylactic reaction |
Angioedema (including laryngeal edema)
|Musculoskeletal and Connective Tissue Disorders||Tendon rupture|
|Nervous System Disorders||Altered coordination |
Myasthenia gravis (exacerbation of)
Peripheral neuropathy (that may be irreversible), polyneuropathy
|Psychiatric Disorders||Psychotic reaction (very rarely culminating in self-injurious behavior, such as suicidal ideation/thoughts or suicide attempts|
|Renal and Urinary Disorders||Interstitial nephritis|
|Respiratory, Thoracic and Mediastinal Disorders||Allergic pneumonitis|
|Skin and Subcutaneous Tissue Disorders||Photosensitivity/phototoxicity reaction |
Toxic epidermal necrolysis
Moxifloxacin Tablets contraindications
Moxifloxacin Tablets tablets are contraindicated in persons with a history of hypersensitivity to Moxifloxacin Tablets or any member of the quinolone class of antibacterials.
Active ingredient matches for Moxifloxacin Tablets:
List of Moxifloxacin Tablets substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Moxifloxacin-ratiopharm (Germany, Hungary)|
|Moxifloxacina Aurobindo (Portugal)|
|Moxifloxacina La Santé (Colombia, Costa Rica, Ecuador, Panama)|
|Moxifloxacina MK (Colombia)|
|Moxifloxacina Vesalius (Colombia)|
|Moxifloxacine Double-E Pharma (Netherlands)|
|Moxifloxacine EG (Belgium, France)|
|Moxifloxacine Fresenius Kabi (Netherlands)|
|Moxifloxacine Krka (France)|
|Moxifloxacine Mylan (Belgium)|
|Moxifloxacine PCH (Netherlands)|
|Moxifloxacine Sandoz (France, Netherlands)|
|Moxifloxacine Teva (Belgium, Netherlands)|
|Moxifloxacino Actavis (Spain)|
|Moxifloxacino Apotex (Spain)|
|Moxifloxacino Aurobindo (Spain)|
|Moxifloxacino Cinfa (Spain)|
|Moxifloxacino Kern Pharma (Spain)|
|Moxifloxacino Krka (Spain)|
|Moxifloxacino MK (Colombia)|
|Moxifloxacino Mylan (Spain)|
|Moxifloxacino Qualigen (Spain)|
|Moxifloxacino Ratiopharm (Spain)|
|Moxifloxacino Sandoz (Spain)|
|Moxifloxacino Stada (Spain)|
|Moxifloxacino Tevagen (Spain)|
|Moxifloxacino Zentiva (Spain)|
|Moxiforce (South Korea)|
|MOXIFORD EYE DROP 1 packet / 5 ML eye drop each (Leeford Healthcare Ltd)||$ 1.05|
|Moxiford 400mg Tablet (Leeford Healthcare Ltd)||$ 0.62|
|Moxifresh NA Eye Drop (Smart Laboratories Pvt Ltd)||$ 0.30|
|MOXIGEN EYE DROP 1 packet / 5 ML eye drop each (Renova Life sciences Pvt Ltd)||$ 1.13|
|Moxigen 0.5% w/v Eye Drop (Renova Life sciences Pvt Ltd)||$ 1.13|
|MOXIGOOD 400 MG TABLET 1 strip / 5 tablets each (Cadila Pharmaceuticals Ltd)||$ 1.75|
|Moxigood 400mg Tablet (Cadila Pharmaceuticals Ltd)||$ 0.35|
|Moxigood 400mg Injection (Cadila Pharmaceuticals Ltd)||$ 0.03|
|Moxigram (Bangladesh, India)|
|Moxigram 0.5% EYE-DPS / 5ml (Micro Vision)||$ 1.16|
|0.5 % x 5ml (Micro Vision)||$ 1.16|
|MOXIGRAM 400 MG TABLET 1 strip / 5 tablets each (Micro Vision)||$ 1.84|
|MOXIGRAM D EYE DROP 1 packet / 10 ML eye drop each (Micro Vision)||$ 1.71|
- PubChem. "moxifloxacin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "moxifloxacin". http://www.drugbank.ca/drugs/DB00218 (accessed September 17, 2018).
- Wikipedia. "moxifloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Moxifl... (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Moxifloxacin Tablets are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moxifloxacin Tablets. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology